



PTO/SB/08A (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2**Complete if Known**

Application Number	10/533,838
Filing Date	May 4, 2005
First Named Inventor	Brown
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	100885-1P US

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
/BR/		US- 2,898,339	08-04-1959	Wheeler et al.	
BAIK		US- 4,581,171	04-08-1986	Kennis et al.	
BAIK		US- 4,816,586	03-28-1989	Portoghese	
BAIK		US- 4,939,137	07-03-1990	Russell et al.	
BAIK		US- 5,140,029	08-18-1992	Kennis et al.	
BAIK		US- 5,574,159	11-12-1996	Chang et al.	
BAIK		US- 5,683,998	11-04-1997	Shibayama et al.	
BAIK		US- 6,187,792	02-13-2001	Delorme et al.	
BAIK		US- 6,455,545	09-24-2002	Delorme et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)				
BAIK		WO 93/15062	08-05-1993	The Wellcome Foundation		
BAIK		WO 97/23466	07-03-1997	Astra Aktiebolag		
BAIK		WO 98/28275	07-02-1998	Astra Pharma Inc.		
BAIK		WO 99/33806	07-08-1999	Ortho-McNeil Pharmaceutical		
BAIK		WO 01/74804	10-11-2001	AstraZeneca AB		
BAIK		WO 01/74806	10-11-2001	AstraZeneca AB		

Examiner Signature	/Binta Robinson/	Date Considered	05/11/2007
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/533,838
		Filing Date	May 4, 2005
		First Named Inventor	Brown
		Art Unit	1614
		Examiner Name	Unknown
Sheet 2	of 2	Attorney Docket Number	100885-1P US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BMR		BARBER, A. et al., "Antinociceptive effects of the 5-HT ₂ Antagonist Ritanserin in Rats: Evidence... in the Spinal Cord," Neuroscience Letters, 1989, Vol. 99, pgs 234-238	
BMR		BILSKY, E. et al., "SNC 80, A Selective, Nonpeptidic and Systematically Active Opioid Delta Agonist," J. Pharmacology Experimental Ther., 1995, Vol. 273, pgs. 359-366	
BMR		GREENE T., "Protective Groups in Organic Synthesis," Wiley & Sons, 1982, pgs. 218, 220, 232, 233, 251	
BMR		TAKEMORI, A.E. et al., "Selective Naltrexone-Derived Opioid Receptor Antagonists," Annu. Rev. Pharmacol. Toxicol., 1992, Vol. 32, pgs. 239-269	
BMR		WEI, Z. et al., "N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide A Novel... and its Analogues," J. Med. Chem., 2000, Vol. 43, pgs. 3895-3905	
BMR		ZHANG, X. et al., "Probes for Narcotic Receptor Mediated Phenomena. 26. 1-3 Synthesis... Opioid Receptor Ligands, J. Med. Chem., 1999, Vol. 42, pgs. 5455-5463	

Examiner Signature	<i>Kento Robinson</i>	Date Considered	5/11/07
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.